- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04378543
Safety Evaluation of ART352-L in Subjects Undergoing Posterolateral Spinal Fusion
A Phase 1b/2a Safety Evaluation of ART352-L in Subjects Undergoing Posterolateral Spinal Fusion
Ankasa Regenerative Therapeutics, Inc. (Ankasa) is developing ART352-L, a liposomal formulation of recombinant human Wnt3A protein, that is applied ex vivo, to harvested autologous bone grafts (autograft) to enhance the osteogenic properties of the autograft prior to reimplantation in orthopedic surgeries.
This is a phase 1/2 open label safety evaluation of ART352-L treated autologous bone grafts in patients undergoing posterolateral lumbar spinal fusion to treat single level degenerative spondylolisthesis. The primary objective of the study is to evaluate the safety and tolerability of ART352-L treated local bone autografts in patients being treated for this condition, with the secondary objective to evaluate the rates of early and overall spinal fusion. Additionally, changes in patient mobility and quality of life measures from baseline following treatment with ART352-L will be evaluated.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Gloria Matthews, DVM, PhD
- Phone Number: 404-947-6472
- Email: gmatthews@wnt3.com
Study Contact Backup
- Name: Sanford Madigan, PhD
- Email: smadigan@wnt3.com
Study Locations
-
-
California
-
Los Angeles, California, United States, 90033
- Recruiting
- Keck School of Medicine, University of Southern California
-
Contact:
- Jeffrey Wang, MD
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic
-
Contact:
- Brett Freedman, MD
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Recruiting
- Wexner Medical Center, The Ohio State University
-
Contact:
- Safdar Khan, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female subjects ≥50 years of age scheduled to undergo single level posterolateral lumbar spinal fusion surgery in conjunction with local autograft bone for degenerative spondylolisthesis
- Psychosocially, mentally, and physically able to fully comply with this protocol including the required follow-up visits, the filling out of required forms, and have the ability to understand and give written informed consent
- Willing and able to undergo diagnostic imaging, inclusive of X-rays and CT scans with contrast
- Persistent, disabling pain after at least 6 months of non-surgical intervention (e.g., anti-inflammatory medication, physical therapy, chiropractic care) prior to providing informed consent
- Pre-operative Oswestry Disability Index (ODI) Score ≥30
- Grade 1 or less spondylolisthesis or retrolisthesis
- Absence of neurological motor deficit
- Agree to use a highly reliable method of birth control (male and female subjects) for at least 90 days after administration of Investigational Product (IP) - Women of childbearing potential must have a negative pregnancy test at screening and again ≤7 days prior to surgery. Perimenopausal women must be amenorrheic for at least 12 months prior to the time of providing informed consent to be considered of non-childbearing potential.
- Agree to remain nicotine-free for the duration of their participation in the study
Exclusion Criteria:
- Multiple level spondylolistheses or a primary diagnosis of low back pain syndrome secondary to diseases other than degenerative spondylolisthesis
- Concurrent medications that affect bone homeostasis including, but not limited to, bisphosphonates
- Ongoing / existing infections in or around the surgical site or spine
- Prior lumbar spine arthrodesis
- Concurrent clinically significant autoimmune disorder or systemic inflammatory disease
- Known hypersensitivity to recombinant Wnt proteins
- Use of tobacco; subjects must be nicotine-free at screening and agree to remain nicotine free for the duration of the study
- Use of medications that may impair cell proliferation and bone healing including: chemotherapy, radiation, chronic steroids and immunosuppressive drugs. Note: Medications that may impair cell proliferation are to be discussed with the protocol medical monitor prior to enrollment
- Severe established osteoporosis requiring active treatment e.g., with bone density more than 2.5 standard deviations below the young adult mean with one or more osteoporotic fractures
- A Body Mass index (BMI) ≥ 40 unless documentation clearly demonstrates why BMI is not a primary factor in the subject's decreased mobility
- Chronic opioid use
- History of deep vein thrombosis (DVT) or blood clotting abnormalities
- Uncontrolled diabetes mellitus
- Pre-operative/anesthesia evaluations deeming the subject ineligible for surgery
- Female subjects who are pregnant or intend to become pregnant during the course of the study
- Male subjects, if not infertile or surgically sterilized, who will not agree to use highly-effective contraception or to not donate sperm from screening until at least 90 days after receiving IP
- Active malignancy ≤5 years prior to providing informed consent. EXCEPTIONS: Non-melanotic skin cancer, carcinoma-in-situ of the cervix. NOTE: If there is a history of prior malignancy, the subject must not be receiving other specific treatment for their cancer.
- Concurrent participation in another investigational drug, biologic or device study that could confound study data
- Involvement in or plans to engage in litigation or receiving Worker's Compensation related to neck, back, or leg pain
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: ART252-L
local autologous bone graft will be treated ex vivo once with ART352-L prior to re-implantation into the site of spinal fusion
|
recombinant human Wnt3a protein delivered on liposomes to local autologous bone graft during posterolateral fusion procedures
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and Tolerability
Time Frame: 2 weeks
|
Incidence of adverse events and adverse events of special interest
|
2 weeks
|
Safety and Tolerability
Time Frame: 8 weeks
|
Incidence of adverse events and adverse events of special interest
|
8 weeks
|
Safety and Tolerability
Time Frame: 26 weeks
|
Incidence of adverse events and adverse events of special interest
|
26 weeks
|
Safety and Tolerability
Time Frame: 52 weeks
|
Incidence of adverse events and adverse events of special interest
|
52 weeks
|
Safety and Tolerability
Time Frame: 104 weeks
|
Incidence of adverse events and adverse events of special interest
|
104 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of early fusion
Time Frame: 26 weeks
|
Rate of early fusion using Lenke scoring of computed tomography (CT) scans
|
26 weeks
|
Rate of fusion
Time Frame: 52 weeks
|
Rate of fusion using Lenke scoring of CT scans
|
52 weeks
|
Rate of fusion
Time Frame: 104 weeks
|
Rate of fusion using Lenke scoring of CT scans
|
104 weeks
|
Oswestry Disability Index
Time Frame: 8 weeks
|
Change from baseline in Oswestry Disability Index
|
8 weeks
|
Oswestry Disability Index
Time Frame: 26 weeks
|
Change from baseline in Oswestry Disability Index
|
26 weeks
|
Oswestry Disability Index
Time Frame: 52 weeks
|
Change from baseline in Oswestry Disability Index
|
52 weeks
|
Oswestry Disability Index
Time Frame: 104 weeks
|
Change from baseline in Oswestry Disability Index
|
104 weeks
|
Short Form-36 (SF-36)
Time Frame: 8 weeks
|
Change from baseline in Short Form-36 (SF-36) score
|
8 weeks
|
Short Form-36 (SF-36)
Time Frame: 26 weeks
|
Change from baseline in Short Form-36 (SF-36) score
|
26 weeks
|
Short Form-36 (SF-36)
Time Frame: 52 weeks
|
Change from baseline in Short Form-36 (SF-36) score
|
52 weeks
|
Short Form-36 (SF-36)
Time Frame: 104 weeks
|
Change from baseline in Short Form-36 (SF-36) score
|
104 weeks
|
Visual Analog Scale (VAS) Pain
Time Frame: 8 weeks
|
Change from baseline in Visual Analog Scale (VAS) Pain assessment
|
8 weeks
|
Visual Analog Scale (VAS) Pain
Time Frame: 26 weeks
|
Change from baseline in Visual Analog Scale (VAS) Pain assessment
|
26 weeks
|
Visual Analog Scale (VAS) Pain
Time Frame: 52 weeks
|
Change from baseline in Visual Analog Scale (VAS) Pain assessment
|
52 weeks
|
Visual Analog Scale (VAS) Pain
Time Frame: 104 weeks
|
Change from baseline in Visual Analog Scale (VAS) Pain assessment
|
104 weeks
|
Patient Reported Outcomes Measurement Information System (PROMIS) - Global 10
Time Frame: 8 weeks
|
Change from baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Global-10 Score
|
8 weeks
|
Patient Reported Outcomes Measurement Information System (PROMIS) - Global 10
Time Frame: 26 weeks
|
Change from baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Global-10 Score
|
26 weeks
|
Patient Reported Outcomes Measurement Information System (PROMIS) - Global 10
Time Frame: 52 weeks
|
Change from baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Global-10 Score
|
52 weeks
|
Patient Reported Outcomes Measurement Information System (PROMIS) - Global 10
Time Frame: 104 weeks
|
Change from baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Global-10 Score
|
104 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ART-SPF-ART352L-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Degenerative Spondylolisthesis
-
NuVasiveCompletedDegenerative Disc Disease | Degenerative Scoliosis | Degenerative SpondylolisthesisUnited States
-
NuVasiveCompletedDegenerative Disc Disease | Degenerative Scoliosis | Degenerative SpondylolisthesisUnited States
-
Jos M. A. KuijlenNot yet recruitingDegenerative Spondylolisthesis | Spondylolytic Spondylolisthesis
-
Zimmer BiometCompletedDegenerative Disc Disease | Degenerative SpondylolisthesisUnited States
-
Seton Healthcare FamilyCelling BiosciencesWithdrawnDegenerative Disc Disease | Spinal Stenosis | Degenerative Spondylolisthesis | Isthmic-lytic SpondylolisthesisUnited States
-
Lahey ClinicDePuy SynthesActive, not recruitingLumbar Spondylolisthesis | Lumbar Spondylosis | Degenerative SpondylolisthesisUnited States
-
Titan SpineTerminated
-
National Taiwan University HospitalRecruitingDegenerative Disc Disease | Degenerative Spondylolisthesis | Degenerative Intervertebral Discs | Degenerative Lumbar Spinal StenosisTaiwan
-
University Hospital, BordeauxCompletedDegenerative SpondylolisthesisFrance
-
Mesoblast, Ltd.CompletedSpinal Stenosis | Cervical Degenerative Disc Disease | Degenerative SpondylolisthesisUnited States
Clinical Trials on ART352-L
-
University of ManitobaMicropharma LimitedCompleted
-
Juliano CasonattoUnknown
-
Sidney Kimmel Cancer Center at Thomas Jefferson...United States Department of DefenseActive, not recruitingColorectal Adenoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage 0 Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal... and other conditionsUnited States
-
Marc-André Maheu-CadotteCompletedHeart Failure | MotivationCanada
-
Massachusetts General HospitalNeurocentria, Inc.CompletedADHD | Attention Deficit/Hyperactivity DisorderUnited States
-
Asklepion Pharmaceuticals, LLCVanderbilt UniversityCompletedHypertension, Pulmonary | Heart Defects, CongenitalUnited States
-
University of OregonNational Institute on Aging (NIA); Oregon Health and Science University; University... and other collaboratorsUnknownQuality of Life | Muscle AtrophyUnited States
-
Gdansk University of Physical Education and SportMedical University of GdanskCompleted
-
Epstein, Arthur B., OD, FAAOAlcon ResearchCompleted